Wellington Management Group
NRIX icon

Wellington Management Group’s Nurix Therapeutics NRIX Stock Holding History

Wellington Management Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.98M Buy
321,360
+46,182
+17% +$766K ﹤0.01% 1405
2025
Q4 		$5.22M Buy
275,178
+19,388
+8% +$279K ﹤0.01% 1404
2025
Q3 		$2.36M Sell
255,790
-1,209,263
-83% -$12.6M ﹤0.01% 1591
2025
Q2 		$16.7M Sell
1,465,053
-1,723,689
-54% -$18.6M ﹤0.01% 1032
2025
Q1 		$37.9M Sell
3,188,742
-397,863
-11% -$6.65M 0.01% 770
2024
Q4 		$67.6M Buy
3,586,605
+104,500
+3% +$2.4M 0.01% 635
2024
Q3 		$78.2M Buy
3,482,105
+280,240
+9% +$6.35M 0.01% 593
2024
Q2 		$66.8M Buy
3,201,865
+2,968,729
+1,273% +$46.2M 0.01% 635
2024
Q1 		$3.43M Buy
233,136
+27,812
+14% +$299K ﹤0.01% 1419
2023
Q4 		$2.12M Buy
205,324
+60,271
+42% +$413K ﹤0.01% 1483
2023
Q3 		$1.14M Buy
145,053
+4,163
+3% +$38K ﹤0.01% 1586
2023
Q2 		$1.41M Buy
140,890
+70,361
+100% +$718K ﹤0.01% 1548
2023
Q1 		$626K Sell
70,529
-2,475
-3% -$25.8K ﹤0.01% 1792
2022
Q4 		$802K Sell
73,004
-1,525
-2% -$18.4K ﹤0.01% 1688
2022
Q3 		$971K Buy
74,529
+21,425
+40% +$339K ﹤0.01% 1661
2022
Q2 		$673K Sell
53,104
-789,269
-94% -$8.95M ﹤0.01% 1750
2022
Q1 		$11.8M Sell
842,373
-319,943
-28% -$5.68M ﹤0.01% 1161
2021
Q4 		$33.6M Sell
1,162,316
-63,742
-5% -$1.93M 0.01% 955
2021
Q3 		$36.7M Sell
1,226,058
-168,833
-12% -$5.21M 0.01% 914
2021
Q2 		$37M Buy
1,394,891
+34,465
+3% +$1.01M 0.01% 925
2021
Q1 		$42.3M Sell
1,360,426
-1,087,158
-44% -$41.1M 0.01% 848
2020
Q4 		$80.3M Sell
2,447,584
-920,938
-27% -$30.5M 0.01% 647
2020
Q3 		$117M Buy
+3,368,522
New +$84.9M 0.02% 489

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Wellington Management Group's NRIX Position: Q1 2026 in Review

Wellington Management Group increased its Nurix Therapeutics (NRIX) stake by 17% in Q1 2026, buying an estimated $766K and bringing the position to 321,360 shares worth $4.98M. The position accounts for ﹤0.01% of the portfolio, ranked #1405.

Wellington Management Group first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. The position peaked at $117M in Q3 2020. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Wellington Management Group held 321,360 shares of Nurix Therapeutics worth $4.98M as of Q1 2026.
  • Wellington Management Group bought 46,182 Nurix Therapeutics shares in Q1 2026, an estimated $766K.
  • Nurix Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q1 2026, its #1405 holding.
  • Wellington Management Group first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Wellington Management Group's Nurix Therapeutics position peaked at $117M in Q3 2020.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.